Project Grant K08AG090815
Award Date 9/9/25
Completion Date 7/31/30
Dollars Obligated $163K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
- This federal Project Grant award of $223,813 from the National Institute on Aging (CFDA 93.866 Aging Research) supports a 2-year cross-sectional and longitudinal study in Nigeria to investigate the use of plasma biomarkers, social determinants of health, and lifestyle factors in classifying and predicting mild cognitive impairment and Alzheimer's disease. The study will enroll 264 participants across three cognitive status groups (Alzheimer's disease, mild cognitive impairment, and healthy...
- This federal Project Grant award of $3,188,901.00 from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to better understand the relationships between in-vivo biomarkers for amyloid, tau, and neurodegeneration (ATN), neuropsychiatric symptoms, vascular risk factors, and genetic risks in Alzheimer's disease. The study will leverage data from large research cohorts like the Alzheimer's Disease Neuroimaging Initiative to develop and optimize machine learning models that can...
- The National Institute on Aging (NIA) awarded a $154,748 Project Grant under the Aging Research program (CFDA 93.866) to Brigham & Women's Hospital Inc. to develop an ultrasensitive blood-based diagnostic tool for accurately determining the presence and severity of Alzheimer's disease (AD). The project aims to utilize single molecule detection to measure low abundance AD protein biomarkers, particularly phosphorylated tau proteins, in blood extracellular vesicles, which can reflect protein...
- This Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) provides $320,143 to Mayo Clinic to assess the diagnostic and disease biomarker utility of blood plasma measures in patients with atypical Alzheimer's disease (AD). The 2-year project aims to determine if plasma biomarkers can differentiate atypical AD patients from healthy controls and other clinical syndromes, as well as evaluate if the plasma biomarkers correlate with clinical...
- This Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) provides $1,550,462 to support a 5-year cross-sectional, longitudinal, and observational study investigating the impact of Alzheimer's disease (AD) risk genes, with a focus on APOE E4, on brain function in older Black/African American individuals living with HIV. The project aims to enroll 120 participants with HIV (60 with and 60 without the APOE E4 allele) and 80 demographically...
- This $2,365,042 Project Grant was awarded by the National Institute on Aging (NIA) under the Aging Research Federal Grant Program (CFDA 93.866) to conduct research on the biological underpinnings of Alzheimer's disease and related dementias (ADRD). The research aims to better characterize the interplay between biological markers of neurodegeneration, vascular, nutritional, and inflammatory systems, and their interface with social and economic factors, by leveraging cross-national comparisons...
- This federal Project Grant award for $528,876, provided by the National Institute on Aging (CFDA 93.866 Aging Research), supports research to investigate the cis- and trans-genetic regulation of brain transcriptomics and proteomics associated with Alzheimer's disease (AD) and AD-related dementias (ADRD). The key goals of the project are to: Estimate genome-wide cis- and trans-acting quantitative trait loci (QTLs) effects for transcriptome-wide genes and proteome-wide proteins across 4 brain...
- This Project Grant award of $437,875 from the National Institute on Aging's Aging Research program (CFDA 93.866) will fund a 2-year research project at the University of California, San Diego to quantify neurovascular protein lifetimes in the central nervous system under healthy, aging, and Alzheimer's disease conditions. The key objectives are to generate a comprehensive atlas of neurovascular protein lifetimes and identify changes associated with aging and Alzheimer's disease. The project will...
- This $5,789,766 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will examine the effects of intensive blood pressure control on mild cognitive impairment, dementia, and plasma biomarker trajectories by Alzheimer's disease pathology. The study aims to elucidate neuroprotective effects in the racially and ethnically diverse SPRINT trial cohort. The University of Utah is the primary awardee and will conduct this research over a period of approximately 5...
- This federal Project Grant award, valued at $1,552,000.00 and provided by the National Institute on Aging (CFDA 93.866 - Aging Research), supports a research study examining the relationship between markers of vascular and immune dysfunction, such as platelet aggregation and neutrophil levels, and their association with dementia risk and increased Alzheimer's disease (AD) biomarkers. The study, conducted by New York University School of Medicine, aims to integrate biofluid biomarker data with...